Abstract Purpose The efficacy of the combination of finasteride and flutamide in select patients with advanced prostatic cancer is determined. Materials and Methods A total of 22 sexually active patients with stages C and D1 carcinoma of the prostate was treated with finasteride plus flutamide. Mean followup was 22 months. Results Initial mean prostate specific antigen level was 42.9 ng./ml. At 3 and 6 months, the mean prostate specific antigen level was 3.6 ng./ml. and 2.9 ng./ml., respectively. The results appear durable at 24 months. Side effects were minimal, with 86 percent of the men maintaining sexual function. Conclusions Finasteride plus flutamide should be considered in sexually active patients with minimal volume advanced prostate cancer.